Loading stock data…
BAX
$17.21-0.37 (-2.10%)
Market ClosedLast close May 1
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Baxter International Inc. in the Healthcare sector is trading at $17.21. The stock is currently near its 52-week low of $15.73, remaining 16.8% below its 200-day moving average. Technical signals show neutral RSI of 46 and bearish MACD signal, explaining why BAX maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 46) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$17.21
Potential Upside
5%
Whystock Fair Value$18.07
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus13 analysts
Hold
Mean target$22.12+28.5%
Range$18.00 – $40.00
Fundamentals
Baxter International Inc., through its subsidiaries, provides a portfolio of healthcare products in the United States. The company operates through three segments: Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals. ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$9.45B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.62
Div Yield
Strong income play. Yield provides a meaningful total return floor.
195.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-2.53%
Volume
Today's trading volume
9.34M
Recent News
Baxter (BAX) Q1 2026 Earnings Call Transcript
Joining me today are Andrew Hider, President and Chief Executive Officer; and Anita Zielinski, Interim Chief Financial Officer, Chief Accounting Officer and Controller. During the call, we will be making forward-looking statements, including comments regarding our reiterated financial outlook for the full year 2026 and the anticipated drivers of the second quarter and second half 2026 performance.
Evercore Cuts Baxter (BAX) Price Target, Keeps Outperform Rating
Baxter International (NYSE:BAX) is one of the 10 Best Medical Stocks to Buy Under $30. On April 6, Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Baxter International (NYSE:BAX) from $23 to $22 while maintaining an Outperform rating on the stock. This comes as part of the firm’s first-quarter preview of the […]
Baxter International Inc. Q1 2026 Earnings Call Summary
Moby summary of Baxter International Inc.'s Q1 2026 earnings call
BAX Stock Gains on Q1 Earnings & Sales Beat, Margins Contract
Baxter beats Q1 earnings and revenue estimates, sending shares higher despite declining profits and margin contraction.
Baxter (BAX) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.